131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma

The newly developed radiopharmaceutical, 131I-metaiodobenzylguanidine (131I-MIBG), has been shown to be efficacious for the location of intra- and extra-adrenal, primary pheochromocytomas and metastatic, malignant pheochromocytomas (11.4% false-negative and 1.8% false-positive in patients with prove...

Full description

Saved in:
Bibliographic Details
Published inCardiology Vol. 72 Suppl 1; p. 137
Main Authors Shapiro, B, Sisson, J C, Eyre, P, Copp, J E, Dmuchowski, C, Beierwaltes, W H
Format Journal Article
LanguageEnglish
Published Switzerland 1985
Subjects
3-Iodobenzylguanidine
Adrenal Gland Neoplasms - diagnostic imaging
Adrenal Gland Neoplasms - radiotherapy
Adrenal Glands - diagnostic imaging
Catecholamines - metabolism
Humans
Iodine Radioisotopes - therapeutic use
Iodobenzenes - therapeutic use
Pheochromocytoma - diagnostic imaging
Pheochromocytoma - radiotherapy
Radionuclide Imaging
Online AccessGet more information

Cover

More Information
Summary:The newly developed radiopharmaceutical, 131I-metaiodobenzylguanidine (131I-MIBG), has been shown to be efficacious for the location of intra- and extra-adrenal, primary pheochromocytomas and metastatic, malignant pheochromocytomas (11.4% false-negative and 1.8% false-positive in patients with proven pheochromocytomas). Preliminary experience in selected patients with malignant pheochromocytoma suggest that therapy using large doses of 131I-MIBG results in partial tumor regression and improvement in catecholamine hypersecretion in some cases.
ISSN:0008-6312
DOI:10.1159/000173960